U.S. Markets
Lilly's (LLY) oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials
Related stocks
1 stocksWhat do investors think?
Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactionsStockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.
